1-6 of 6
Dirk Garmann
Close
Sort by
Journal Articles

Pooled Exposure-Response (ER) and Quantitative Benefit/Risk (B/R) Analyses Support the Approved Copanlisib Intermittent Dosing Regimen

Peter N Morcos, Jonathan Moss, Charles Phelps, Florian JR Hiemeyer, Barrett H. Childs, Martin Dreyling, Pier Luigi Zinzani, Dirk Garmann
Journal: Blood
Blood (2023) 142 (Supplement 1): 6156.
https://doi.org/10.1182/blood-2023-187153
Published: 2023
Journal Articles

Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma

Jonathan Moss, Dirk Garmann, Rupert Austin, Florian Hiemeyer, Matthew J. Matasar, Pier Luigi Zinzani, Vita Beckert, Lidia Mongay Soler, Barrett H. Childs, Peter N. Morcos
Journal: Blood
Blood (2022) 140 (Supplement 1): 3629–3631.
https://doi.org/10.1182/blood-2022-162819
Published: 2022
Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients Treated for Venous Thromboembolism

Scott D. Berkowitz, MD, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Keith A A Fox, MBBS, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann
Journal: Blood
Blood (2017) 130 (Supplement 1): 1104.
https://doi.org/10.1182/blood.V130.Suppl_1.1104.1104
Published: 2017
Journal Articles

The Effect of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in Patients with Nonvalvular Atrial Fibrillation

Xiaoyu Yan, PhD MSc, Gary Peters, MD, Amarnath Sharma, Partha Nandy, Christopher Nessel, MD, Dirk Garmann, Stefan Willmann, Anne Hermanowski-Vosatka, Alexander Solms, Scott D. Berkowitz, MD, Theodore E Spiro, MD, Keith A A Fox, MBBS, Jeffrey I Weitz, MD FRCPC, FACP, Stephan Schmidt, Jonathan P Piccini, Manesh Patel, Richard C Becker, Liping Zhang
Journal: Blood
Blood (2017) 130 (Supplement 1): 1107.
https://doi.org/10.1182/blood.V130.Suppl_1.1107.1107
Published: 2017
Journal Articles

The Effects of Rivaroxaban Exposure and Clinical Risk Factors on Efficacy and Safety Outcomes in the Prevention of Venous Thromboembolism after Elective Hip or Knee Replacement Surgery

Scott D. Berkowitz, MD, Keith A A Fox, MBBS, Stephan Schmidt, Jeffrey I Weitz, MD FRCPC, FACP, Dirk Garmann, Dagmar Kubitza, Wolfgang Mueck, Gary Peters, MD, Isabel Reinecke, Alexander Solms, Theodore E Spiro, MD, Xiaoyu Yan, PhD MSc, Liping Zhang, Stefan Willmann
Journal: Blood
Blood (2017) 130 (Supplement 1): 3718.
https://doi.org/10.1182/blood.V130.Suppl_1.3718.3718
Published: 2017
Journal Articles

New Approach in Assessing the Pharmacokinetic/Pharmacodynamic Relationship in Patients with Severe Hemophilia A Using Data from BAY 81-8973 Studies

Dirk Garmann, Matthias Frede, Anita Shah, Bart Ploeger
Journal: Blood
Blood (2015) 126 (23): 1095.
https://doi.org/10.1182/blood.V126.23.1095.1095
Published: 2015